Through data gathered in a DRC-sponsored research project, Peter Thompson, Ph.D., was able to secure additional funding that generated the results in this paper. Researchers explored the effects of senescent beta cells – or aging cells that no longer divide – on the development of type 1 diabetes (T1D).
In individuals with T1D, the body’s immune system attacks and destroys insulin-producing beta cells that are necessary for regulating blood glucose levels. However, researchers have found that senescent beta cells increase B-cell lymphoma 2 (Bcl-2) proteins, which in turn regulate cell death or apoptosis. By using a Bcl-2 inhibitor, researchers were able to eliminate senescent beta cells from the body which helps to stop the immune system’s destruction of insulin-producing beta cells and prevents the development of T1D.
This could be a major step forward in using the elimination of senescent beta cells as a therapeutic approach to treating or preventing T1D. More research is necessary to further explore the potential of this approach, but this study sheds new light on how the process impacts T1D and provides a greater understanding of the pathogenesis of the disease.
The Diabetes Research Connection (DRC) is proud to have played a role in providing the initial funding to enable Dr. Thompson and his team to collect necessary data to move forward and receive additional funding for the study. The DRC empowers early career scientists to pursue novel research studies on T1D through the support of individual, corporate, and foundation donations.